---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-002070"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T09:01:35.814061+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medtronic makes $90M strategic investment in Anteris; combined $320M capital raise

## Summary
- Medtronic invested $90M in Anteris via stock purchase; Anteris also completed an underwritten common stock offering for total gross proceeds of $320M.
- Proceeds to fund global pivotal PARADIGM trial and global commercialization of DurAVR THV (transcatheter heart valve).
- PARADIGM trial is a randomized controlled trial of ~1000 patients comparing DurAVR THV to commercially available TAVRs; enrollment started Q4 2025.
- Medtronic and Anteris may expand collaboration into other strategic areas; Medtronic joins Anteris' stockholder community.

## SEC filing metadata
- accession: 0001140361-26-002070
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036126002070/0001140361-26-002070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036126002070/ny20062007x8_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-002070
- JSON: https://secwatch.observer/filing/0001140361-26-002070.json
- Plain text: https://secwatch.observer/filing/0001140361-26-002070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.